5-Amino-1MQ common uses, half-life, side effects and more

5-Amino-1MQ is a small molecule that blocks an enzyme called NNMT. Sellers list it with peptides even though it is a different kind of molecule. People take it for fat loss and body recomposition. Most swallow it as capsules. Vials for injection are also sold. It has never been approved for any use in any country. No human trial of it has ever been run. The US Food and Drug Administration named the substance in a warning letter in January 2026. That letter told an outsourcing facility the substance could not lawfully be used in compounding. It is sold online as a research chemical and cannot lawfully be sold as a supplement.

• Fat loss and body recomposition
• Glucose handling and metabolic health
• Muscle function and strength in older age
• Raising NAD+ levels
• Longevity and healthy aging stacks

Once daily

Community practice is 50 to 150 mg by mouth once daily. Most oral reports land at 100 mg. Injected practice has not converged. A telehealth and compounding channel doses 1 mg under the skin once daily for eight to twelve weeks. Self-directed users inject 5 to 50 mg under the skin once daily and most of them settle near 25 mg. Those two conventions sit twenty-five fold apart and nothing accounts for the gap. No human dose has been established for either route. Every animal study that showed an effect injected the compound rather than feeding it.

• Check whether a product is labeled in milligrams or micrograms because supplement capsules at 500 mcg and research capsules at 50 mg both sell under this name
• A stated milligram amount may describe the salt rather than the active portion and the iodide salt is roughly 44 percent counterion by weight
• Cycling advice circulates in conflicting versions running from four weeks on and four weeks off to twelve-week blocks
• A 25 mg injection will not fit a normal syringe volume at usual peptide concentrations and users pool several vials into one cartridge at roughly 85 mg per mL

No human pharmacokinetic study of this compound exists. Rat studies report a terminal half-life of 3.8 hours after an intravenous dose and 6.9 hours after an oral one. Mouse values run longer at 6.3 hours intravenously and about 13 hours under the skin. The two species disagree roughly ten-fold on how much of an oral dose reaches the blood.

• No human trial has ever been run and nothing is known about how this compound behaves in people
• Nausea, headache, and trouble sleeping turn up in scattered user reports at unknown frequency
• The side-effect lists on vendor pages trace to no study, no trial, and no safety monitoring
• Mouse studies reported no deaths or visible ill effects and none of them was designed to detect harm
• A single injected user with existing histamine intolerance reported a whole-body histamine reaction within minutes at 10 mg

NNMT takes a methyl group from the body's main methyl donor and attaches it to nicotinamide. Blocking the enzyme should spare both the nicotinamide that cells use to build NAD+ and the methyl donor itself. That is the theory the compound is sold on. Cultured fat cells treated with it did show more NAD+ and more methyl donor. NAD+ has never been measured in the tissue of a living animal given this compound. The in-body NAD+ result usually cited for it comes from silencing the gene in a different laboratory by a different method. Muscle cells treated with the drug showed no NAD+ change at all and their NAD+ to NADH ratio fell. It leaves the related methyl-transferring enzymes alone and its grip on its own target is weak.

Almost every study of this compound comes from a single university laboratory. Ten of the twelve animal studies carry the same two researchers. The head of that laboratory founded the company holding the patents and its staff wrote the newest metabolic paper. The founding obesity result used nine mice per group over eleven days for about a five percent weight difference. No laboratory outside that group has ever reproduced a metabolic effect with this molecule. Two independent groups have used it in animals and both studied tumors. A different molecule aimed at the same enzyme produced weight loss in obese mice in independent hands. That supports the enzyme as a target rather than this particular compound. No human data exists and no toxicology study has ever been published in any species.

• Users who inject settle on amounts inside the swallowed range even though injecting skips the absorption losses and delivers far more of the compound
• No toxicology study of this compound exists in any species and nothing has tested it for genetic damage, cancer risk, or harm to a pregnancy
• No human has ever taken this compound in a study and the longest animal study of any kind ran about eight weeks
• Sellers claim it has been shown not to damage DNA and no published study supports that claim
• Taking it alongside NAD+ precursors such as nicotinamide, nicotinamide riboside, or NMN has never been studied and this enzyme is the body's main route for clearing excess nicotinamide
• Athletes will not find it by name on the anti-doping list and the category covering substances with no approval anywhere still prohibits it at all times